ArticleThe oncologist2025
A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Synchronous Esophageal Squamous Cell Carcinoma and Gastric Cardia Adenocarcinoma with Hepatoid Differentiation After Neoadjuvant Chemoimmunotherapy.Journal of clinical medicine · 2026Article
- Rare Gastroesophageal Tumor Subtypes: Clinicopathologic Characteristics, Molecular Alterations, and Therapeutic Implications.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aims to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1) blockade in combination with chemotherapy for patients with advanced hepatoid adenocarcinoma of the stomach (HAS). MATERIALS AND
methodsThis study retrospectively collected data from 25 patients with advanced HAS who received first-line PD-1 blockade combined with chemotherapy across 6 centers between January 2018 and January 2024. Progression-free survival and overall survival were assessed using Kaplan-Meier curves.
resultsThis study included 25 patients with HAS, all of whom received a first-line treatment regimen combining PD-1 blockade and chemotherapy. The objective response rate and disease control rate were 76.0% and 88.0%, respectively. The median follow-up time was 13.1 months, with a median progression-free survival of 10.2 months (95% CI, 6.3-14.1) and a median overall survival of 20.3 months (95% CI, 11.3-29.4). A total of 20 patients (80.0%) experienced adverse reactions of varying degrees, with white blood cell count decreased (12, 48.0%) being the most common adverse event. Two patients experienced fatal adverse events (grade 5), both of which were unrelated to the PD-1 blockade.
conclusionsPatients with HAS can derive survival benefits from first-line treatment with PD-1 blockade combined with chemotherapy, and the treatment is well tolerated. Furthermore, this pathological subtype may serve as a predictive indicator of favorable efficacy for PD-1 blockade, regardless of the patients' programmed death-ligand 1 combined positive score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.